Third Security LLC raised its position in Intrexon Corporation (NYSE:XON) by 0.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 62,435,495 shares of the biotechnology company’s stock after acquiring an additional 134,169 shares during the quarter. Intrexon Corporation makes up about 76.4% of Third Security LLC’s holdings, making the stock its biggest holding. Third Security LLC owned about 52.20% of Intrexon Corporation worth $1,504,071,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in XON. Federated Investors Inc. PA purchased a new position in Intrexon Corporation in the 2nd quarter valued at $172,000. Pacer Advisors Inc. boosted its position in shares of Intrexon Corporation by 21.6% during the 1st quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 1,305 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Intrexon Corporation during the 1st quarter worth $164,000. Cullinan Associates Inc. purchased a new stake in shares of Intrexon Corporation during the 2nd quarter worth $201,000. Finally, Principal Financial Group Inc. purchased a new stake in shares of Intrexon Corporation during the 2nd quarter worth $212,000. 82.27% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Intrexon Corporation (NYSE:XON) is Third Security LLC’s Largest Position” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://ledgergazette.com/2017/09/17/third-security-llc-buys-134169-shares-of-intrexon-corporation-xon.html.
In other news, Director Robert B. Shapiro bought 2,850 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was acquired at an average cost of $17.50 per share, with a total value of $49,875.00. Following the transaction, the director now directly owns 43,157 shares of the company’s stock, valued at approximately $755,247.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Randal J. Kirk purchased 132,625 shares of the business’s stock in a transaction on Friday, August 11th. The shares were bought at an average price of $18.85 per share, with a total value of $2,499,981.25. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 144,569 shares of company stock valued at $2,719,429. 55.10% of the stock is owned by corporate insiders.
Several brokerages have commented on XON. Zacks Investment Research lowered shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. BidaskClub upgraded shares of Intrexon Corporation from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 15th. Finally, Northland Securities set a $30.00 target price on shares of Intrexon Corporation and gave the company a “buy” rating in a research note on Monday, August 7th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. Intrexon Corporation presently has a consensus rating of “Hold” and an average price target of $37.60.
Shares of Intrexon Corporation (NYSE:XON) opened at 19.37 on Friday. The firm’s market cap is $2.33 billion. The company’s 50-day moving average is $19.56 and its 200-day moving average is $21.42. Intrexon Corporation has a 52-week low of $17.04 and a 52-week high of $32.90.
Intrexon Corporation (NYSE:XON) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The company had revenue of $54.40 million for the quarter, compared to the consensus estimate of $57.17 million. During the same quarter last year, the business posted ($0.42) EPS. Intrexon Corporation’s revenue for the quarter was up 3.6% on a year-over-year basis. Equities research analysts forecast that Intrexon Corporation will post ($0.87) earnings per share for the current fiscal year.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.